PMID- 7778529
OWN - NLM
STAT- MEDLINE
DCOM- 19950713
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 75
IP  - 18
DP  - 1995 Jun 16
TI  - Multicenter, randomized, placebo-controlled, double-blind study of the safety and 
      efficacy of oral delapril in patients with congestive heart failure.
PG  - 18F-24F
AB  - A total of 101 patients (67 delapril, 34 placebo) with congestive heart failure, 
      New York Heart Association (NYHA) classes II and III, entered a multicenter, 
      randomized (2:1), double-blind, placebo-controlled study to determine the minimum 
      effective and maximum tolerated doses of delapril. Patients received placebo or 
      increasing doses of delapril. After a 2-week run-in period on placebo, patients 
      were randomly assigned to delapril or placebo. The dose of delapril was 7.5 mg 
      twice daily for 2 weeks, 15 mg twice daily for another 2 weeks, followed by 30 mg 
      twice daily for 4 weeks. The dose was increased only if the patient did not 
      present any symptoms of orthostatic hypotension. If such symptoms developed, the 
      code was broken and an open treatment was continued on the minimum effective dose 
      (delapril group). Patients with symptoms of orthostatic hypotension in the 
      placebo group were withdrawn. At the end of the 8-week treatment, 36 (54.5%) 
      patients in the delapril group completed the study on 30 mg twice daily, 12 
      (18.2%) on 15 mg twice daily, and 18 (27.3%) on 7.5 mg twice daily. Seven 
      patients on placebo were withdrawn because of insufficient therapeutic response; 
      one patient on delapril was lost to follow-up. There was a significant 
      improvement (p < 0.01) in bicycle ergometric performance involving an increase in 
      the exercise duration and the maximum workload tolerated in those patients 
      completing the study on delapril 30 mg twice daily and those finishing on 15 mg 
      twice daily.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Circo, A
AU  - Circo A
AD  - Institute of Oncology Santi Curro e Luigi Gonzaga, Catania, Italy.
FAU - Platania, F
AU  - Platania F
FAU - Mangiameli, S
AU  - Mangiameli S
FAU - Putignano, E
AU  - Putignano E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Indans)
RN  - W77UAL9THI (delapril)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Analysis of Variance
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Double-Blind Method
MH  - Exercise Test/drug effects
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Indans/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 1995/06/16 00:00
MHDA- 1995/06/16 00:01
CRDT- 1995/06/16 00:00
PHST- 1995/06/16 00:00 [pubmed]
PHST- 1995/06/16 00:01 [medline]
PHST- 1995/06/16 00:00 [entrez]
AID - S0002-9149(99)80510-4 [pii]
AID - 10.1016/s0002-9149(99)80510-4 [doi]
PST - ppublish
SO  - Am J Cardiol. 1995 Jun 16;75(18):18F-24F. doi: 10.1016/s0002-9149(99)80510-4.